HU0003001D0 - A novel crystalline form of 6-hydroxy-3-(4-[2(piperidin-1-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride - Google Patents

A novel crystalline form of 6-hydroxy-3-(4-[2(piperidin-1-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride

Info

Publication number
HU0003001D0
HU0003001D0 HU0003001A HUP0003001A HU0003001D0 HU 0003001 D0 HU0003001 D0 HU 0003001D0 HU 0003001 A HU0003001 A HU 0003001A HU P0003001 A HUP0003001 A HU P0003001A HU 0003001 D0 HU0003001 D0 HU 0003001D0
Authority
HU
Hungary
Prior art keywords
piperidin
benzo
methoxyphenyl
phenoxy
ethoxy
Prior art date
Application number
HU0003001A
Other languages
Hungarian (hu)
Inventor
Julie Kay Bush
Preston Charles Conrad
Merlyn Gerard Flom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HU0003001D0 publication Critical patent/HU0003001D0/en
Publication of HUP0003001A2 publication Critical patent/HUP0003001A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0003001A 1999-07-29 2000-07-28 A novel crystalline form of 6-hydroxy-3-(4-[2(piperidin-1-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride and pharmaceutical composition containing the same HUP0003001A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14628699P 1999-07-29 1999-07-29
US14757099P 1999-08-06 1999-08-06
US14977399P 1999-08-19 1999-08-19

Publications (2)

Publication Number Publication Date
HU0003001D0 true HU0003001D0 (en) 2000-10-28
HUP0003001A2 HUP0003001A2 (en) 2002-04-29

Family

ID=27386379

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003001A HUP0003001A2 (en) 1999-07-29 2000-07-28 A novel crystalline form of 6-hydroxy-3-(4-[2(piperidin-1-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride and pharmaceutical composition containing the same

Country Status (45)

Country Link
EP (1) EP1204656A2 (en)
JP (1) JP2001064277A (en)
KR (1) KR100697177B1 (en)
CN (1) CN1138770C (en)
AR (1) AR031073A1 (en)
AT (1) AT502318A1 (en)
AU (1) AU6335600A (en)
BE (1) BE1013411A3 (en)
BR (1) BR0003209A (en)
CA (1) CA2314682A1 (en)
CO (1) CO5180570A1 (en)
CZ (1) CZ299311B6 (en)
DE (1) DE10036854A1 (en)
DK (1) DK200001151A (en)
DZ (1) DZ3060A1 (en)
FI (1) FI20001722A (en)
FR (1) FR2796944B1 (en)
GB (1) GB2352717A (en)
GR (1) GR1004084B (en)
HK (1) HK1035370A1 (en)
HR (1) HRP20000503B1 (en)
HU (1) HUP0003001A2 (en)
ID (1) ID27078A (en)
IL (1) IL137553A (en)
IT (1) IT1318660B1 (en)
LT (1) LT4790B (en)
LU (1) LU90617B1 (en)
LV (1) LV12623B (en)
MD (1) MD2336G2 (en)
MX (1) MXPA00007461A (en)
MY (1) MY128764A (en)
NL (1) NL1015821C2 (en)
NO (1) NO20003879L (en)
PE (1) PE20010385A1 (en)
PL (1) PL341749A1 (en)
PT (1) PT102502A (en)
RO (1) RO121851B1 (en)
SE (1) SE0002792L (en)
SG (1) SG91296A1 (en)
SI (1) SI20426A (en)
SV (1) SV2002000132A (en)
TR (1) TR200002206A2 (en)
TW (1) TWI276437B (en)
UA (1) UA72885C2 (en)
WO (1) WO2001009116A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1204655B1 (en) * 1999-07-29 2003-10-01 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
DZ3376A1 (en) * 2000-05-08 2001-11-15 Lilly Co Eli STABILIZED FORMULATIONS OF 6-HYDROXY-3- (4- [2- (PIPERIDIN-1-YL) ETHOXY] PHENOXY) -2- (4-METHOXYPHENYL) BENZO [B] THIOPHENE AND SALTS THEREOF
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
EP1157996A1 (en) * 2000-05-23 2001-11-28 JENAPHARM GmbH New solid forms of mesoprogestin 11beta-(4E-(hydroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on
US20040014672A1 (en) * 2000-10-20 2004-01-22 Luke Wayne Douglas Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
AU2002230409A1 (en) 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
JP4922163B2 (en) * 2004-07-22 2012-04-25 イーライ リリー アンド カンパニー (S) -6- (4- (2-((3- (9H-carbazol-4-yloxy) -2-hydroxypropyl) amino) -2-methylpropyl) phenoxy) -3-pyridinecarboxamide hemisuccinate Crystalline nonstoichiometric hydrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3989569B2 (en) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー Benzothiophene compounds, intermediates, compositions and methods
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
ZA9710262B (en) * 1996-11-19 1999-05-13 Lilly Co Eli Process for the synthesis of benzothiophenes
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.

Also Published As

Publication number Publication date
SE0002792L (en) 2001-01-30
NL1015821A1 (en) 2001-01-30
PT102502A (en) 2001-01-31
ID27078A (en) 2001-02-22
MD20000162A (en) 2001-04-30
CA2314682A1 (en) 2001-01-29
PE20010385A1 (en) 2001-04-06
KR20010049916A (en) 2001-06-15
CN1138770C (en) 2004-02-18
FI20001722A (en) 2001-01-30
BE1013411A3 (en) 2001-12-04
IT1318660B1 (en) 2003-08-27
MY128764A (en) 2007-02-28
CN1288007A (en) 2001-03-21
WO2001009116A3 (en) 2001-05-17
GR20000100265A (en) 2001-03-30
SE0002792D0 (en) 2000-07-28
HUP0003001A2 (en) 2002-04-29
SV2002000132A (en) 2002-06-07
TR200002206A2 (en) 2001-03-21
UA72885C2 (en) 2005-05-16
FR2796944B1 (en) 2003-01-31
FR2796944A1 (en) 2001-02-02
FI20001722A0 (en) 2000-07-28
MXPA00007461A (en) 2004-07-16
ITMI20001759A0 (en) 2000-07-28
DZ3060A1 (en) 2004-05-22
EP1204656A2 (en) 2002-05-15
CZ299311B6 (en) 2008-06-18
LU90617B1 (en) 2001-06-15
DE10036854A1 (en) 2001-03-01
MD2336G2 (en) 2004-06-30
AR031073A1 (en) 2003-09-10
IL137553A0 (en) 2001-07-24
RO121851B1 (en) 2008-06-30
AT502318A1 (en) 2007-02-15
NL1015821C2 (en) 2002-01-03
TWI276437B (en) 2007-03-21
CZ20002716A3 (en) 2001-05-16
LT4790B (en) 2001-05-25
LV12623A (en) 2001-03-20
GB0018641D0 (en) 2000-09-13
DK200001151A (en) 2001-01-30
SG91296A1 (en) 2002-09-17
GR1004084B (en) 2002-12-11
JP2001064277A (en) 2001-03-13
AU6335600A (en) 2001-02-19
HK1035370A1 (en) 2001-11-23
IE20000605A1 (en) 2001-04-04
HRP20000503A2 (en) 2001-06-30
KR100697177B1 (en) 2007-03-21
MD2336F2 (en) 2003-12-31
NO20003879L (en) 2001-01-30
ITMI20001759A1 (en) 2002-01-28
LT2000076A (en) 2001-02-26
SI20426A (en) 2001-06-30
PL341749A1 (en) 2001-02-12
CO5180570A1 (en) 2002-07-30
BR0003209A (en) 2001-03-20
WO2001009116A2 (en) 2001-02-08
IL137553A (en) 2005-09-25
LV12623B (en) 2001-07-20
GB2352717A (en) 2001-02-07
NO20003879D0 (en) 2000-07-28
HRP20000503B1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
IL137552A0 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
HU0003001D0 (en) A novel crystalline form of 6-hydroxy-3-(4-[2(piperidin-1-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
IL155487A0 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2- (PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
ZA200003837B (en) A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
ZA200003838B (en) A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
IL152699A0 (en) STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO [b] THIOPHENE AND SALTS THEREOF
TJ20000620A (en) A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxy Ü phenoxy) - 2 - (4-methanoxyphenyl) benzo ÄbÜ thiophene hidrochloride
TJ398B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees